* Chemocentryx announces presentation of positive results
from Phase II ANCA-associated vasculitis clear trial of orally
administered complement 5a receptor inhibitor CCX168 at the 53rd
ERA-EDTA…
The post BRIEF-Chemocentryx says treatment with CCX168 successful in achieving clinical efficacy endpoints appeared first on NASDAQ.